サンプル依頼リスト カート
  • English
  • Korean
表紙：AV-101新薬の考察と市場予測（2032年）
市場調査レポート
商品コード
1173589

AV-101新薬の考察と市場予測（2032年）

AV-101 Emerging Drug Insight and Market Forecast - 2032
出版日: 受注後更新 | 発行: DelveInsight | ページ情報: 英文 30 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
AV-101新薬の考察と市場予測（2032年）
出版日: 受注後更新
発行: DelveInsight
ページ情報: 英文 30 Pages
納期: 2～10営業日
ご注意事項 :
本レポートの納品は、最新情報反映のため受注時に適宜更新しお届けいたします。
更新情報の反映作業にあたり納期もレポート毎に異なりますので、ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、AV-101新薬の主要7市場（米国・ドイツ・フランス・イタリア・スペイン・英国・日本）について調査分析し、作用機序、用法と用量、研究開発活動についての考察、市場予測などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 肺動脈性肺高血圧症におけるAV-101の概要

  • 製品の詳細
  • 臨床開発
    • 臨床研究
    • 臨床試験情報
  • その他の開発活動
  • 製品プロファイル

第3章 競合情勢（上市済みの治療法）

第4章 競合情勢（後期の新しい治療法）

第5章 AV-101の市場の評価

  • 肺動脈性肺高血圧症におけるAV-101の市場の見通し
  • 主要7市場の分析
    • 主要7市場の肺動脈性肺高血圧症向けAV-101の市場規模
  • 市場の分析：国別
    • 米国の肺動脈性肺高血圧症向けAV-101の市場規模
    • ドイツの肺動脈性肺高血圧症向けAV-101の市場規模
    • 英国の肺動脈性肺高血圧症向けAV-101の市場規模

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

図表

List of Tables

  • Table 1: AV-101, Clinical Trial Description, 2022
  • Table 2: AV-101: General Description
  • Table 3: Competitive Landscape ( Marketed Therapies)
  • Table 4: Competitive Landscape (Emerging Therapies)
  • Table 5:AV-101 Market Size in the 7MM, in USD million (2019-2032)
  • Table 6:AV-101 Market Size in the United States, in USD million (2019-2032)
  • Table 7:AV-101 Market Size in Germany, in USD million (2019-2032)
  • Table 8:AV-101 Market Size in France, in USD million (2019-2032)
  • Table 9:AV-101 Market Size in Italy, in USD million (2019-2032)
  • Table 10:AV-101 Market Size in Spain, in USD million (2019-2032)
  • Table 11:AV-101 Market Size in the United Kingdom, in USD million (2019-2032)
  • Table 12:AV-101 Market Size in Japan, in USD million (2019-2032)

List of Figures

  • Figure 1: Market Size of AV-101 in the 7MM, in USD million (2019-2032)
  • Figure 2: Market Size of AV-101 in the United States, in USD million (2019-2032)
  • Figure 3: Market Size of AV-101 in Germany, in USD million (2019-2032)
  • Figure 4: Market Size of AV-101 in France, in USD million (2019-2032)
  • Figure 5: Market Size of AV-101 in Italy, in USD million (2019-2032)
  • Figure 6: Market Size of AV-101 in Spain, in USD million (2019-2032)
  • Figure 7: Market Size of AV-101 in the United Kingdom, in USD million (2019-2032)
  • Figure 8:Market Size of AV-101 in Japan, in USD million (2019-2032)
目次
Product Code: DIDM0558

"AV-101 Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about AV-101 for Pulmonary Arterial Hypertension in the 7MM. A detailed picture of the AV-101 for Pulmonary Arterial Hypertension in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019-2032 is provided in this report along with a detailed description of the AV-101 for Pulmonary Arterial Hypertension. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the AV-101 market forecast, analysis for Pulmonary Arterial Hypertension in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about emerging therapies in Pulmonary Arterial Hypertension.

Drug Summary:

Investigational AV-101 is a novel dry powder formulation of the FDA approved therapy Imatinib. Dosed specifically for PAH, the AV-101 is designed for delivery by a dry powder inhaler, directly into the lungs to halt the proliferation of cells, improving heart function and everyday health.

Imatinib is an oral inhibitor of several protein kinases implicated in the pathophysiology of pulmonary hypertension.

Through its inhibitory effect on platelet-derived growth factor signaling, Imatinib could be efficacious in treating patients with Pulmonary Arterial Hypertension (PAH).

 

Scope of the Report:

The report provides insights into:

  • A comprehensive product overview including the AV-101 description, mechanism of action, dosage and administration, research and development activities in Pulmonary Arterial Hypertension.
  • Elaborated details on AV-101 regulatory milestones and other development activities have been provided in this report.
  • The report also highlights the AV-101 research and development activity in Pulmonary Arterial Hypertension details across the United States, Europe and Japan.
  • The report also covers the patents information with expiry timeline around AV-101.
  • The report contains forecasted sales of AV-101 for Pulmonary Arterial Hypertension till 2032.
  • Comprehensive coverage of the late-stage emerging therapies for Pulmonary Arterial Hypertension.
  • The report also features the SWOT analysis with analyst views for AV-101 in Pulmonary Arterial Hypertension.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

 

AV-101 Analytical Perspective by DelveInsight

  • In-depth AV-101 Market Assessment

This report provides a detailed market assessment of AV-101 in Pulmonary Arterial Hypertension in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2026 to 2032.

  • AV-101 Clinical Assessment

The report provides the clinical trials information of AV-101 for Pulmonary Arterial Hypertension covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

  • In the coming years, the market scenario for Pulmonary Arterial Hypertension is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence AV-101 dominance.
  • Other emerging products for Pulmonary Arterial Hypertension are expected to give tough market competition to AV-101 and launch of late-stage emerging therapies in the near future will significantly impact the market.
  • A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of AV-101 in Pulmonary Arterial Hypertension.
  • Our in-depth analysis of the forecasted sales data of AV-101 from 2026 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the AV-101 in Pulmonary Arterial Hypertension.

 

Key Questions

  • What is the product type, route of administration and mechanism of action of AV-101?
  • What is the clinical trial status of the study related to AV-101 in Pulmonary Arterial Hypertension and study completion date?
  • What are the key collaborations, mergers and acquisitions, licensing and other activities related to the AV-101 development?
  • What are the key designations that have been granted to AV-101 for Pulmonary Arterial Hypertension?
  • What is the forecasted market scenario of AV-101 for Pulmonary Arterial Hypertension?
  • What are the forecasted sales of AV-101 in the 7MM, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
  • What are the other emerging products available in Pulmonary Arterial Hypertension and how are they giving competition to AV-101 for Pulmonary Arterial Hypertension?
  • Which are the late-stage emerging therapies under development for the treatment of Pulmonary Arterial Hypertension?

Table of Contents

1. Report Introduction

2. AV-101 Overview in Pulmonary Arterial Hypertension

  • 2.1 Product Detail
  • 2.2 Clinical Development
    • 2.2.1 Clinical Studies
    • 2.2.2 Clinical Trials information
  • 2.3 Other Development Activities
  • 2.4 Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)*

5. AV-101 Market Assessment

  • 5.1 Market Outlook of AV-101 in Pulmonary Arterial Hypertension
  • 5.2 7MM Market Analysis
    • 5.2.1 Market Size of AV-101 in the 7MM for Pulmonary Arterial Hypertension
  • 5.3 Country-wise Market Analysis
    • 5.3.1 Market Size of AV-101 in the United States for Pulmonary Arterial Hypertension
    • 5.3.2 Market Size of AV-101 in Germany for Pulmonary Arterial Hypertension
    • 5.3.3 Market Size of AV-101 in France for Pulmonary Arterial Hypertension
    • 5.3.4 Market Size of AV-101 in Italy for Pulmonary Arterial Hypertension
    • 5.3.5 Market Size of AV-101 in Spain for Pulmonary Arterial Hypertension
    • 5.3.6 Market Size of AV-101 in the United Kingdom for Pulmonary Arterial Hypertension
    • 5.3.7 Market Size of AV-101 in Japan for Pulmonary Arterial Hypertension

6. SWOT Analysis

7. Analysts' Views

8. Appendix

  • 8.1 Bibliography
  • 8.2 Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Option